The Filing Desk

bioAffinity Technologies vs Seer

bioAffinity Technologies BIAF · Seer SEER · Life Sciences Tools & Services

Seer reported revenue of $17 million in fiscal 2025, 2.7 times bioAffinity Technologies' $6 million in fiscal 2025. bioAffinity Technologies' revenue fell 34.2% in its latest year, and Seer's grew 17.0%. bioAffinity Technologies had an operating margin of -171.6%, against -470.4% at Seer. Free cash flow was −$9 million at bioAffinity Technologies and −$46 million at Seer.

Side by side

bioAffinity TechnologiesSeer
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$6M$17M
Revenue growth−34.2%17.0%
Revenue growth a year, last 5 years—88.4%
Gross margin—51.1%
Operating margin−171.6%−470.4%
Net margin−242.0%−444.0%
Free cash flow−$9M−$46M
Free cash flow margin−152.4%−278.9%
Return on capital−400.1%—
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count325.8%—
Last close$1.85$1.39
P/E at the last close——
Insider trades, last 12 monthsbought $1.0 million, sold $1.2 millionsold $117,931
Piotroski F-score3 of 8—
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
bioAffinity TechnologiesSeer
Operating margin
Percent of revenue
bioAffinity TechnologiesSeer
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
bioAffinity TechnologiesSeer

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the bioAffinity Technologies and Seer pages.